The potential economic value of a Staphylococcus aureus vaccine for neonates

Bruce Y. Lee, Paul J. Ufberg, Rachel R. Bailey, Ann E. Wiringa, Kenneth J. Smith, Andrew J. Nowalk, Conor Higgins, Angela R. Wateska, Robert R. Muder

Research output: Contribution to journalArticle

Abstract

The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (≤$500), and S. aureus attack rates (≥1%).

Original languageEnglish (US)
Pages (from-to)4653-4660
Number of pages8
JournalVaccine
Volume28
Issue number29
DOIs
StatePublished - Jun 23 2010

    Fingerprint

Keywords

  • Economics
  • Staphylococcus aureus
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lee, B. Y., Ufberg, P. J., Bailey, R. R., Wiringa, A. E., Smith, K. J., Nowalk, A. J., Higgins, C., Wateska, A. R., & Muder, R. R. (2010). The potential economic value of a Staphylococcus aureus vaccine for neonates. Vaccine, 28(29), 4653-4660. https://doi.org/10.1016/j.vaccine.2010.04.069